atrial natriuretic factor

Atrial natriuretic factor (1-28) from both human and porcine sources is a potent suppressor of pro-opiomelanocortin (POMC) mRNA, exerting only a modest inhibitory effect on βEP-LI release.

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.

Atrial Natriuretic Peptide (1-28), rat is the major circulating form of ANP in rats.

Prepro-Atrial Natriuretic Factor (26-55) (human) is a polypeptide that increases cyclic GMP levels in the renal cortex and medulla, and enhances renal guanylate cyclase activity [1].

Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits antihypertensive activity by promoting sodium and urine excretion. It inhibits the release of adrenocorticotropic hormone (ACTH) and β-endorphin by suppressing pro-opiomelanocortin (POMC) expression. Additionally, it elevates cGMP levels in RMIC cells, with an IC50 of 1.2 nM.

Prepro-ANF (56-92), human, a precursor to the human atrial natriuretic factor, activates guanylate cyclase by specifically enhancing particulate guanylate cyclase activity within the renal membrane and unit [1].

Auriculin A, a synthetic atrial natriuretic factor (ANF), exhibits hemodynamic properties by antagonizing renal vasoconstriction in dogs and affects arterial baroreflex regulation of heart rate, systemic blood pressure, and constant flow-perfused hind limb perfusion pressure in rabbits [1] [2].

ANP (1-11), rat acetate (Atrial natriuretic factor (1-11) acetate) is one of the atrial natriuretic factors, inhibitors of CRF-stimulated ACTH secretion.